1-aminomethyl-1-hydroxy-7-chlorotetralin | 246261-93-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 1-aminomethyl-1-hydroxy-7-chlorotetralin
• 英文别名: 1-(aminomethyl)-7-chloro-3,4-dihydro-2H-naphthalen-1-ol
• CAS: 246261-93-8
• 化学式: C₁₁H₁₄ClNO
• 分子量: 211.691
• InChiKey: JMXFQNKMAHSGNI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Propanolamine derivatives
  申请人：Fujisawa Pharmaceutical Co. Ltd.

  公开号：US20020120148A1

  公开（公告）日：2002-08-29

  This invention relates to new propanolamine derivatives or salts thereof represented by the following formula [I]: 1 Wherein each symbol is as defined in the specification or salts thereof which have gut selective sympathomimetic, anti-ulcerous, anti-pancreatitis, lipolytic, anti-urinary incontinence and anti-pollakiuria activities, to processes for the preparation thereof, to a pharmaceutical composition comprising the same and to a method for the prevention and/or treatment diseases indicated in the specification to a human being or an animal.

  这项发明涉及新的丙醇胺衍生物或其盐，其化学式如下所示：1其中每个符号如规范中定义，或具有选择性肠道交感神经兴奋作用、抗溃疡、抗胰腺炎、脂解作用、抗尿失禁和抗尿频活性的盐，以及其制备方法、包含相同的药物组合物以及用于预防和/或治疗规范中指示的疾病的方法，适用于人类或动物。
• Fused imidazole derivative
  申请人：——

  公开号：US20040198791A1

  公开（公告）日：2004-10-07

  According to the present invention, fused imidazole derivatives of the general formula: 1 wherein R 1 is a hydrogen atom, a halogen atom, hydroxy group, a lower alkyl group or a lower alkoxy group, R 2 is an aryl group, benzodioxanyl group, or 5-6 membered, monocyclic, unsaturated, heterocyclic group containing nitrogen atom(s) which may be substituted with lower alkyl, trityl or oxo, R 3 is a hydrogen atom or hydroxy group, A is a group represented by the formula: —(CH 2 ) m — or —O—(CH 2 ) m — [wherein m is an integer of 1-3] and their salts are provided.

  根据本发明，提供了一般式为：1的熔融咪唑衍生物，其中R1为氢原子、卤素原子、羟基、低碳基或低氧基；R2为芳基、苯二氧基基团或含有氮原子的5-6成员单环不饱和杂环基团，可被低碳基、三苯基或氧代取代；R3为氢原子或羟基；A为以下式子所代表的基团：—(CH2)m—或—O—(CH2)m—[其中，m为1-3的整数]及其盐。
• Use of beta 3 adrenergic receptor agonists in the treatment of dysuria
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP1382333A2

  公开（公告）日：2004-01-21

  The application relates to the use of a β3 adrenergic receptor agonist selected from the group consisting of formulas (IV),(V),(VI),(VII) and (VIII) for the manufacture of a medicament for the prophylactic and/or the therapeutic treatment of dysuria. In the above formulae, the various groups, substituents and variables have the meanings given in the description.

  本申请涉及选自式(IV)、(V)、(VI)、(VII)和(VIII)组成的组中的β3 肾上腺素能受体激动剂的用途。 用于制造预防和/或治疗排尿困难的药物。在上式中，各基团、取代基和变量具有说明中给出的含义。
• FUSED IMIDAZOLE DERIVATIVE
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP1403256A1

  公开（公告）日：2004-03-31

  According to the present invention, fused imidazole derivatives of the general formula: wherein R1 is a hydrogen atom, a halogen atom, hydroxy group, a lower alkyl group or a lower alkoxy group, R2 is an aryl group, benzodioxanyl group, or 5-6 membered, monocyclic, unsaturated, heterocyclic group containing nitrogen atom(s) which may be substituted with lower alkyl, trityl or oxo, R3 is a hydrogen atom or hydroxy group, A is a group represented by the formula : -(CH2)m - or -O-(CH2)m- [wherein m is an integer of 1-3] and their salts are provided.

  根据本发明，通式如下的融合咪唑衍生物 其中 R1 是氢原子、卤素原子、羟基、低级烷基或低级烷氧基、 R2 是芳基、苯并二恶烷基或含有氮原子的 5-6 位单环、不饱和杂环基团，可被低级烷基、三烷基或氧代取代、 R3 是氢原子或羟基，A 是由式：-(CH2)m-或-O-(CH2)m-[其中 m 为 1-3 的整数]。 以及它们的盐。
• US6495546B1
  申请人：——

  公开号：US6495546B1

  公开（公告）日：2002-12-17